While there are no studies proving their value in ARVC patients, there are many trials demonstrating the critical role of ACE inhibitor therapy in patients with ischemic and non-ischemic forms of dilated cardiomyopathy. This evidence concerns the gene ACE and Arrhythmogenic right ventricular dysplasia.